What it is

Triple agonist at GLP-1, GIP, and glucagon receptors; a newer metabolic-class research tool.

Also known as

GLP-3 RT · RETA · Triple agonist (GLP-1/GIP/glucagon)

Overview

Retatrutide is a synthetic peptide agonist engineered to engage three metabolic receptors—GLP-1, GIP, and glucagon—in a single ligand. In published preclinical and clinical-development literature it is positioned as a multi-incretin research tool for studying energy balance, glycemic signaling, and body-composition endpoints.

Laboratory interest centers on how concurrent incretin and glucagon-pathway activation compares with single- or dual-agonist designs. Left Turn Adventures supplies this compound for laboratory and research use only.

Proven benefits

Note: Preclinical / literature endpoints for labs — not established human treatment benefits. Not a protocol.

• Multi-receptor incretin/glucagon signaling endpoints in metabolic models

• • Appetite and energy-intake readouts in GLP-class research designs

• • Glycemic and insulin-related markers in metabolic studies

• • Body-composition and adipose-tissue endpoints where reported

• • Comparative pharmacology versus dual and single GLP/GIP agonists

Results timeline

Note: Illustrative research-observation windows — not a clinical schedule. No dosing.

• Week 1–2: Early receptor-engagement and appetite/energy-signaling readouts in model systems; compound exposure establishing.

• • Week 3–4: Clearer metabolic and satiety-pathway markers in short preclinical windows.

• • Month 2–3: More stable body-composition and glucose/lipid-related endpoints where studied.

• • Month 3–6: Sustained metabolic-signaling observations in longer research designs.

Footer RUO

The catalog, not a clinic

For laboratory and research use only. Not for human or animal consumption. Products are sold solely to qualified researchers and licensed laboratories. No dosing or reconstitution on this page.